Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pazopanib Hydrochloride

FDA-approved product (tablet, oral), marketed as Pazopanib Hydrochloride, Votrient.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Pazopanib Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chromophobe renal cell carcinoma
  • Clear cell renal carcinoma
  • Collecting duct carcinoma
  • Papillary renal cell carcinoma
  • Renal cell carcinoma
  • Sarcoma
  • Soft tissue sarcoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pazopanib Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pazopanib Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

    NCT00454363 · start 2007-03

    Registered record
    Registry ID
    NCT00454363
    Conditions
    Gastrin-Producing Neuroendocrine Tumor; Lung Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Multiple Endocrine Neoplasia Type 1; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Recurrent Pancreatic Neuroendocrine Carcinoma; Regional Digestive System Neuroendocrine Tumor G1; Somatostatin-Producing Neuroendocrine Tumor
    Interventions
    Laboratory Biomarker Analysis; Pazopanib Hydrochloride; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-03
    Completion
    2014-12
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrin-Producing Neuroendocrine Tumor; Lung Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Multiple Endocrine Neoplasia Type 1 +7 more
    InterventionLaboratory Biomarker Analysis; Pazopanib Hydrochloride; Pharmacological Study
    PhasePhase 2
    Registry statusCompleted

  • Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

    NCT00459862 · start 2007-03

    Registered record
    Registry ID
    NCT00459862
    Conditions
    Advanced Malignant Mesothelioma; Localized Malignant Mesothelioma; Recurrent Malignant Mesothelioma
    Interventions
    laboratory biomarker analysis; pazopanib hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-03
    Completion
    2013-05
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Malignant Mesothelioma; Localized Malignant Mesothelioma; Recurrent Malignant Mesothelioma
    Interventionlaboratory biomarker analysis; pazopanib hydrochloride
    PhasePhase 2
    Registry statusCompleted

  • Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery

    NCT00450879 · start 2007-01

    Registered record
    Registry ID
    NCT00450879
    Conditions
    Male Breast Carcinoma; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer
    Interventions
    Pazopanib Hydrochloride; Dynamic Contrast-Enhanced Magnetic Resonance Imaging; Pharmacological Study; Laboratory Biomarker Analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2007-01
    Completion
    2011-09
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMale Breast Carcinoma; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer +3 more
    InterventionPazopanib Hydrochloride; Dynamic Contrast-Enhanced Magnetic Resonance Imaging; Pharmacological Study; Laboratory Biomarker Analysis
    PhasePhase 1
    Registry statusTerminated

  • Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer

    NCT00454571 · start 2006-06

    Registered record
    Registry ID
    NCT00454571
    Conditions
    Recurrent Prostate Cancer
    Interventions
    pazopanib hydrochloride; leuprolide acetate; goserelin acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-06
    Completion
    2010-12
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Prostate Cancer
    Interventionpazopanib hydrochloride; leuprolide acetate; goserelin acetate
    PhasePhase 2
    Registry statusCompleted

  • GW786034 in Treating Patients With Advanced Solid Tumors

    NCT00060151 · start 2002-12

    Registered record
    Registry ID
    NCT00060151
    Conditions
    Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    pazopanib hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-12
    Completion
    2009-06
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnspecified Adult Solid Tumor, Protocol Specific
    Interventionpazopanib hydrochloride
    PhasePhase 1
    Registry statusCompleted